External reports (aggregated public sources), Value Investors Club

Value Investors Club

External reports (aggregated public sources)

Equity Bottom-Up

<ul><li>ESPR pharmaceutical company has two commercialized drugs and could potentially double in value with a $300 million milestone payout</li><li>Ongoing litigation with DSE due to failure to meet payment obligations under a milestone agreement</li><li>ESPR entitled to a Regulatory Milestone Payment pending regulatory approval for a licensed product in DSE territory, making it a strong investment opportunity with potential for high returns</li></ul><p><em>This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.</em></p>

ESPR pharmaceutical company has two commercialized drugs and could potentially double in value with a $300 million milestone payoutOngoing litigation with DSE due to failure to meet payment obligations under a milestone agreementESPR entitled to a Regulatory Milestone Payment pending regulatory approval for a licensed product in DSE territory, making it a strong investment opportunity with potential for high returnsThis content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.

Esperion Therapeutics Inc (ESPR) - Friday, Dec 22, 2023

United States

Esperion Therapeutics, Inc. develops and markets medical devices. The Company produces oral, small molecule therapies for the treatment of patients with elevated levels of low-density lipoprotein cholesterol and other cardio metabolic risk factors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00